Semax and Selank are two of the most frequently referenced peptides in nootropic and cognitive research literature. Both originated from the same Russian pharmacological research program the Institute of Molecular Genetics of the Russian Academy of Sciences, in collaboration with the V.V. Zakusov Research Institute of Pharmacology and both have drawn sustained academic interest for their proposed interactions with neuropeptide pathways [1][4]. This article examines what differentiates these two compounds, what current peer-reviewed literature explores, and what researchers should understand about responsible, compliant research practices.
This article is intended strictly for educational and informational purposes. It does not promote, endorse, or encourage the use of peptides for human consumption, self-administration, cognitive enhancement, or the diagnosis, treatment, cure, or prevention of any disease. Semax and Selank are discussed here only as Research Use Only (RUO) laboratory compounds. Neither peptide is approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use in the United States, and both should be handled exclusively within a qualified research setting.
What Is Semax?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the N-terminal (4–10) fragment of adrenocorticotropic hormone (ACTH), modified to retain neuropeptide activity while lacking the hormonal effects of the parent molecule [2][3]. It originated from Russian neuropharmacology research and has since become a frequently cited compound in neuropeptide research literature.
• A synthetic ACTH(4-10)-fragment analog, heptapeptide in structure [2]
• Originally developed within Russian pharmacological research programs
• Studied in preclinical models examining neurotrophic factor gene expression [3][5]
• Distributed strictly as an RUO compound for laboratory investigation
Semax Research Focus Areas
Laboratory research has documented that a single intranasal application of Semax in rat models produces measurable increases in brain-derived neurotrophic factor (BDNF) protein and messenger RNA levels in the hippocampus, along with increased tyrosine phosphorylation of the TrkB receptor, which BDNF normally activates [2]. Separate research has also examined Semax’s effects on nerve growth factor (NGF) and BDNF gene expression across multiple brain regions, and on transcriptome-level changes following cerebral ischemia-reperfusion injury in rodent models [3][5]. These findings are specific to controlled preclinical research settings and do not represent established outcomes in humans.
What Is Selank?
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of tuftsin, an endogenous immunomodulatory peptide fragment of immunoglobulin G, extended with a Pro-Gly-Pro sequence to improve metabolic stability [4]. Like Semax, it emerged from Russian pharmacological research and is frequently discussed alongside Semax in comparative neuropeptide literature.
• A synthetic tuftsin analog with an added stabilizing sequence [4]
• Studied for interactions with GABAergic receptor systems in preclinical models [4]
• Referenced in preclinical research examining anxiety-related behavioral models in rodents, including in combination with reference anxiolytic compounds [6]
• Distributed exclusively as an RUO compound for laboratory research
Selank Research Focus Areas
Research literature involving Selank has examined its relationship to gene expression within GABAergic neurotransmission pathways, with researchers proposing that the peptide may bind GABA-A receptor sites and allosterically modulate receptor activity [4]. A separate rodent study examined Selank’s anxiolytic-related behavioral effects when administered alongside a reference benzodiazepine compound under chronic stress conditions, reporting comparable behavioral response patterns between the two [6]. As with Semax, these are laboratory observations that should not be interpreted as evidence of effects in humans.
How Do Semax and Selank Compare?
Structural Origin
• Semax: Derived from an ACTH(4-10) hormone fragment [2]
• Selank: Derived from tuftsin, an immunomodulatory peptide fragment [4]
Proposed Research Mechanisms
• Semax: Studied in relation to neurotrophic factor (BDNF/NGF) gene expression and receptor signaling [2][3][5]
• Selank: Studied in relation to GABAergic receptor gene expression and behavioral research models [4][6]
Why These Two Are Frequently Discussed Together
Semax and Selank are often grouped together in research literature and supplier catalogs because both originate from the same Russian pharmacological research institutions and share the same C-terminal Pro-Gly-Pro stabilizing sequence, a design choice used across both peptides to extend metabolic stability [1][4]. This grouping reflects shared research lineage and structural design strategy, not a confirmed combined mechanism or effect.
Potential Research Areas of Interest
The following areas reflect topics found in published preclinical literature. They describe research interest only not demonstrated human outcomes, cognitive enhancement claims, or guaranteed results of any kind.
• Neurotrophic factor (BDNF/NGF) gene expression and receptor signaling research associated with Semax [2][3][5]
• Cerebral ischemia-reperfusion and transcriptome-level research models associated with Semax [5]
• GABAergic receptor gene expression research associated with Selank [4]
• Comparative rodent behavioral research models associated with Selank [6]
Safety Considerations for Researchers
Because both Semax and Selank are RUO compounds, they must be handled according to strict laboratory protocols:
• Use only within a qualified laboratory or institutional research setting
• Follow institutional biosafety and chemical handling guidelines
• Store lyophilized peptides according to manufacturer specifications, typically frozen or refrigerated
• Maintain documentation of batch numbers and third-party Certificates of Analysis
• Dispose of research materials in accordance with local, state, and federal regulations
Disclaimer: Neither Semax nor Selank has been evaluated or approved by the FDA for human use in the United States. This article does not provide dosing, administration, or self-experimentation guidance. Use of RUO materials outside of a qualified laboratory setting is strongly discouraged and falls outside the intended purpose of these products.
Current Scientific Research
Both peptides continue to appear in international pharmacology literature. Foundational Semax research published in Journal of Neurochemistry and Brain Research established the peptide’s relationship to BDNF and TrkB signaling in rodent hippocampal and basal forebrain tissue [2][7]. Subsequent PubMed-indexed studies examined the time course of Semax’s effects on neurotrophin gene expression across the hippocampus, frontal cortex, and retina [3]. A more recent study published in PMC used transcriptome-level analysis to examine Semax’s protective properties in a rat model of cerebral ischemia-reperfusion, and a separate PMC review of neuroprotective peptides for ischemic stroke drug discovery references Semax among its examples [5][8].
For Selank, PMC-indexed research has examined the peptide’s effects on genes involved in GABAergic neurotransmission, proposing a receptor-level mechanism for its behavioral effects in animal models [4]. A separate PMC-published rodent study examined Selank’s behavioral effects under chronic stress conditions in combination with a reference benzodiazepine compound [6]. Much of the existing literature on both peptides originates from Russian and Eastern European research institutions, which is an important context for researchers to understand when evaluating study design, sample size, and translational relevance to other research settings.
No RUO supplier, including RUO Science, can make claims regarding safety, efficacy, or approved use of these compounds in humans. All information here should be understood strictly within the context of laboratory and academic research, and researchers are encouraged to review the primary literature cited below directly.
Frequently Asked Questions
1. What is the main difference between Semax and Selank?
Semax is derived from a fragment of ACTH and is studied primarily in relation to neurotrophic factor (BDNF/NGF) gene expression and receptor signaling, while Selank is derived from tuftsin and is studied in relation to GABAergic receptor gene expression in behavioral research models [2][4].
2. Are Semax and Selank approved by the FDA?
No. Neither peptide is approved by the FDA for human or veterinary use in the United States. Both are classified as Research Use Only (RUO) and are intended strictly for laboratory research.
3. Why are Semax and Selank often discussed together?
Both peptides originate from the same Russian pharmacological research institutions and share a common Pro-Gly-Pro stabilizing sequence, which is why they are frequently grouped together in literature and supplier catalogs [1][4]. This does not indicate a confirmed combined mechanism.
4. Can Semax or Selank be used for cognitive enhancement or personal use?
No. Neither peptide is approved for human use of any kind, including cognitive enhancement or nootropic applications. They are strictly laboratory research materials intended for use by qualified researchers only.
5. How can researchers verify the quality of Semax or Selank research materials?
Researchers should request a Certificate of Analysis (CoA) from an independent third-party laboratory, confirming purity, identity, and testing methodology such as High-Performance Liquid Chromatography (HPLC) or Mass Spectrometry (MS).
6. Where can I find peer-reviewed research on these peptides?
PubMed and PMC index a range of international pharmacology studies on Semax and Selank, several of which are cited directly in the References section of this article. Researchers should evaluate primary literature directly, paying attention to study design and research origin, rather than relying on supplier marketing claims.
Conclusion
Semax and Selank represent two of the most frequently referenced compounds in nootropic and neuropeptide research literature, each with a distinct structural origin and proposed research mechanism documented in peer-reviewed sources. Semax is studied primarily in relation to neurotrophic factor (BDNF/NGF) pathways, while Selank is examined in the context of GABAergic receptor gene expression in behavioral models. Researchers evaluating either compound should prioritize third-party verified documentation, critical review of peer-reviewed literature, and strict compliance with RUO handling guidelines. Neither compound is approved for human use in the United States, and no cognitive or health outcome should be assumed or implied outside of a qualified laboratory research setting.
This article is for educational purposes only and does not constitute medical, legal, or regulatory advice. Semax and Selank are Research Use Only products not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. Consult applicable FDA guidance and your institution’s research compliance office before handling any RUO material.
References (Cited Sources)
[1] Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission NCBI/PMC (background on Institute of Molecular Genetics origin). https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/
[2] Dolotov et al. (2006). Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of BDNF protein in rat basal forebrain — Journal of Neurochemistry, Wiley Online Library. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1471-4159.2006.03658.x
[3] Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 PubMed. https://pubmed.ncbi.nlm.nih.gov/17353092/
[4] Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission NCBI/PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/
[5] Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats — NCBI/PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC7350263/
[6] Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats — NCBI/PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/
[7] Dolotov et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus — Brain Research, ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S0006899306022955
[8] Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries — NCBI/PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10218113/
